Updated Price Disclosure Guidelines

By Petrina Smith
Tuesday, 26 November, 2013


An updated version of the Price Disclosure Arrangements Procedural and Operational Guidelines for Expanded and Accelerated Price Disclosure has been published.
The updated Guidelines reflect changes made to the National Health (Pharmaceutical  Benefits) Regulations 1960 in April 2013. According to the Department of Health website, those Regulation changes were made following December 2012 litigation concerning inclusion of de-listed brands in price disclosure calculations.  The Guidelines also provide more information about a number of other matters, including:



  • how to disclose data when the commercial responsibility for a brand passes before the legally responsible person has been changed;

  • calculating new premiums for price disclosure reductions;

  • how price disclosure reductions are applied to new brands listing after the end of a data collection period and before the reduction day;


and

  • how reduced prices are adjusted to take account of any change in pricing quantity for brands of a pharmaceutical item between the end of the data collection period and the reduction day


Find out more at http://www.pbs.gov.au/info/industry/pricing/eapd#Explanatory
Related Articles

Robot automates hospital disinfection processes

South Korean researchers have developed an 'intelligent autonomous wiping and UV-C...

Colorectal cancer survivors face elevated risk

Colorectal cancer (CRC) survivors face an elevated risk of developing multiple primary cancers,...

Key concerns this Sarcoma Awareness Month

July is Sarcoma Awareness Month, and the Australia and New Zealand Sarcoma Association has raised...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd